OBJECTIVE: In HIV-infected adults in sub-Saharan Africa, asymptomatic cryptococcal antigenemia at the time of antiretroviral therapy (ART) initiation is associated with more than 20% increased mortality. Provisional recommendations for treatment of asymptomatic cryptococcal antigenemia are neither well substantiated nor feasible in many resource-poor settings. After hospitals in Tanzania implemented a programme providing serum cryptococcal antigen (CrAg) screening with 4-week intensive fluconazole treatment for CrAg-positive patients, we were asked to assess the impact of this programme on mortality. DESIGN: In this retrospective operational research study, we documented 6-month outcomes of HIV-infected adults who had had CD4 cell counts less than 200 cells/μl at the time of starting ART and had been screened for cryptococcal antigenemia over a period of 15 months. METHODS: We randomly selected three CrAg-negative patients, matched for ART start date, for every CrAg-positive patient who had been identified and treated with the 4-week intensive fluconazole course. The primary outcome was 6-month mortality in CrAg-positive and CrAg-negative groups. RESULTS: Mortality of CrAg-positive HIV-infected adults who received short-course fluconazole was noninferior to CrAg-negative adults. At 6 months, 16 of 18 CrAg-positive and 46 of 54 CrAg-negative patients were alive [88.9% versus 85.1%, -3.9% absolute difference (one-sided 90% confidence interval +10.8%)]. No deaths in the CrAg-positive group seemed to be due to cryptococcal meningitis. CONCLUSION: This study suggests that even short-course intensive fluconazole could reduce the mortality of patients with asymptomatic cryptococcal antigenemia. Further studies are needed to confirm if this dose is both optimal for patient survival and feasible for wide implementation in resource-poor settings where mortality of cryptococcal disease is highest.
OBJECTIVE: In HIV-infected adults in sub-Saharan Africa, asymptomatic cryptococcal antigenemia at the time of antiretroviral therapy (ART) initiation is associated with more than 20% increased mortality. Provisional recommendations for treatment of asymptomatic cryptococcal antigenemia are neither well substantiated nor feasible in many resource-poor settings. After hospitals in Tanzania implemented a programme providing serum cryptococcal antigen (CrAg) screening with 4-week intensive fluconazole treatment for CrAg-positive patients, we were asked to assess the impact of this programme on mortality. DESIGN: In this retrospective operational research study, we documented 6-month outcomes of HIV-infected adults who had had CD4 cell counts less than 200 cells/μl at the time of starting ART and had been screened for cryptococcal antigenemia over a period of 15 months. METHODS: We randomly selected three CrAg-negative patients, matched for ART start date, for every CrAg-positive patient who had been identified and treated with the 4-week intensive fluconazole course. The primary outcome was 6-month mortality in CrAg-positive and CrAg-negative groups. RESULTS: Mortality of CrAg-positive HIV-infected adults who received short-course fluconazole was noninferior to CrAg-negative adults. At 6 months, 16 of 18 CrAg-positive and 46 of 54 CrAg-negative patients were alive [88.9% versus 85.1%, -3.9% absolute difference (one-sided 90% confidence interval +10.8%)]. No deaths in the CrAg-positive group seemed to be due to cryptococcal meningitis. CONCLUSION: This study suggests that even short-course intensive fluconazole could reduce the mortality of patients with asymptomatic cryptococcal antigenemia. Further studies are needed to confirm if this dose is both optimal for patient survival and feasible for wide implementation in resource-poor settings where mortality of cryptococcal disease is highest.
Authors: Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison Journal: Lancet Date: 2004-05-29 Impact factor: 79.321
Authors: David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware Journal: Clin Infect Dis Date: 2010-08-15 Impact factor: 9.079
Authors: Sayoki Mfinanga; Duncan Chanda; Sokoine L Kivuyo; Lorna Guinness; Christian Bottomley; Victoria Simms; Carol Chijoka; Ayubu Masasi; Godfather Kimaro; Bernard Ngowi; Amos Kahwa; Peter Mwaba; Thomas S Harrison; Saidi Egwaga; Shabbar Jaffar Journal: Lancet Date: 2015-03-10 Impact factor: 79.321
Authors: Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Cheryl A Liechty; Peter Solberg; Willy Were; John Paul Ekwaru; Ray L Ransom; Paul J Weidle; Robert Downing; Alex Coutinho; Jonathan Mermin Journal: Trop Med Int Health Date: 2007-08 Impact factor: 2.622
Authors: John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: Bahati Mk Wajanga; Samuel Kalluvya; Jennifer A Downs; Warren D Johnson; Daniel W Fitzgerald; Robert N Peck Journal: J Int AIDS Soc Date: 2011-10-11 Impact factor: 5.396
Authors: Kinanga A Magambo; Samuel E Kalluvya; Shikha W Kapoor; Jeremiah Seni; Awilly A Chofle; Daniel W Fitzgerald; Jennifer A Downs Journal: J Int AIDS Soc Date: 2014-08-08 Impact factor: 5.396
Authors: Rachel M Wake; Erika Britz; Charlotte Sriruttan; Ivy Rukasha; Tanvier Omar; David C Spencer; Jeremy S Nel; Sello Mashamaite; Adeboye Adelekan; Tom M Chiller; Joseph N Jarvis; Thomas S Harrison; Nelesh P Govender Journal: Clin Infect Dis Date: 2018-02-10 Impact factor: 9.079
Authors: Paul K Drain; Sean R Galagan; Sabina Govere; Meighan Krows; Hilary Thulare; Carole L Wallis; Bernadett I Gosnell; Mahomed-Yunus Moosa; Connie Celum; Ingrid V Bassett Journal: J Acquir Immune Defic Syndr Date: 2021-08-15 Impact factor: 3.771
Authors: Bruce A Larson; Peter C Rockers; Rachael Bonawitz; Charlotte Sriruttan; Deborah K Glencross; Naseem Cassim; Lindi M Coetzee; Gregory S Greene; Tom M Chiller; Snigdha Vallabhaneni; Lawrence Long; Craig van Rensburg; Nelesh P Govender Journal: PLoS One Date: 2016-07-08 Impact factor: 3.240
Authors: Elvis Temfack; Charles Kouanfack; Leonella Mossiang; Angela Loyse; Marie C Fonkoua; Síle F Molloy; Sinata Koulla-Shiro; Eric Delaporte; Françoise Dromer; Thomas Harrison; Olivier Lortholary Journal: Front Microbiol Date: 2018-03-13 Impact factor: 5.640
Authors: Rita O Oladele; Alani S Akanmu; Augustina O Nwosu; Folasade T Ogunsola; Malcolm D Richardson; David W Denning Journal: Open Forum Infect Dis Date: 2016-03-15 Impact factor: 3.835